Unlabelled: The Seraph100 Microbind Affinity Blood Filter (Seraph 100) (ExThera Medical, Martinez, CA) is an extracorporeal therapy that can remove pathogens from blood, including severe acute respiratory syndrome coronavirus 2. The aim of this study was to evaluate safety and efficacy of Seraph 100 treatment for COVID-19.
Design: Retrospective cohort study.
Setting: Nine participating ICUs.
Patients: COVID-19 patients treated with Seraph 100 ( = 53) and control patients matched by study site ( = 53).
Intervention: Treatment with Seraph 100.
Measurements And Main Results: At baseline, there were no differences between the groups in terms of sex, race/ethnicity, body mass index, and need for mechanical ventilation. However, patients in the Seraph 100 group were younger (median age, 54 yr; interquartile range [IQR], 41-65) compared with controls (median age, 64 yr; IQR, 56-69; = 0.009). Charlson comorbidity index scores were lower in the Seraph 100 group (2; IQR, 0-3) compared with the control group (3; IQR, 2-4; = 0.006). Acute Physiology and Chronic Health Evaluation II scores were also lower in Seraph 100 subjects (12; IQR, 9-17) compared with controls (16; IQR, 12-21; = 0.011). The Seraph 100 group had higher vasopressor-free days with an incidence rate ratio of 1.30 on univariate analysis. This difference was not significant after adjustment. Seraph 100-treated subjects were less likely to die compared with controls (32.1% vs 64.2%; = 0.001), a difference that remained significant after adjustment. However, no difference in mortality was observed in a post hoc analysis utilizing an external control group. In the full cohort of 86 treated patients, there were 177 total treatments, in which only three serious adverse events were recorded.
Conclusions: Although this study did not demonstrate consistently significant clinical benefit across all endpoints and comparisons, the findings suggest that broad spectrum, pathogen agnostic, blood purification can be safely deployed to meet new pathogen threats while awaiting targeted therapies and vaccines.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9049035 | PMC |
| http://dx.doi.org/10.1097/CCE.0000000000000662 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- The study examined 33 severe COVID-19 patients who underwent a novel hemoperfusion therapy using the Seraph100 filter, aiming to reduce viral RNA levels and markers of inflammation.
- Results showed that while the initial levels of SARS-CoV-2 RNA were generally low and did not significantly change post-treatment, five inflammatory protein analytes exhibited notable decreases, indicating some therapeutic effect on inflammation and endothelial damage.
- The conclusion highlighted that Seraph 100 did not effectively lower viral RNA levels, but it did successfully reduce several inflammatory markers in the blood of these patients.
Seraph 100-A new extracorporeal device to decrease elevated sFlt-1 in preeclamptic plasma?
Ther Apher Dial
December 2024
Medical Clinic V, Nephrology, Rheumatology, Blood Purification, Academic Teaching Hospital, Braunschweig, Germany.
Determining the efficacy of ExThera Seraph100 blood filtration in patients diagnosed with pancreatic cancer through the liquid biopsy.
BJC Rep
June 2024
Pancreatic and Biliary Diseases Program, Cedars Sinai Medical Center, Los Angeles, CA, 90048, USA.
Background: Cancer becomes lethal as it spreads from the primary site to the rest of the body. Circulating tumor cells (CTCs) are biomarkers of disease progression and have been associated with decreased overall survival. Blood filtration is a novel concept for removing CTCs from circulation to improve patient prognosis.
View Article and Find Full Text PDFSuccessful Repeated Use of a Pathogen Adsorbing Biomimetic Device for the Adjunct Treatment of a SARS-CoV-2 Reinfection and Subsequent Infections with Different Multiresistant Bacteria.
Case Rep Nephrol Dial
October 2024
Medical Clinic V Nephrology, Rheumatology, Blood Purification, Academic Teaching Hospital Braunschweig, Braunschweig, Germany.
Introduction: The Seraph 100 Microbind Affinity Filter is a biomimetic adsorbent device that can remove pathogens from the blood.
Case Presentation: Here, we report the successful use of the Seraph 100 to treat both a SARS-CoV-2 reinfection leading to severe COVID-19 pneumonia as well as subsequent secondary lung infections including Acinetobacter baumannii, Serratia marcescens, and Pseudomonas aeruginosa multidrug-resistant bacteria. To our knowledge, this 46-year-old black male is the first patient in which four treatments with this pathogen adsorber, one for a viral and three for different bacterial infections, have been successfully used.
The Seraph 100 Microbind Affinity Blood Filter Does Not Alter Levels of Circulating or Mucosal Antibodies in Critical COVID-19 Patients.
Antibodies (Basel)
August 2024
Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
PURIFY-OBS-1 is an observational study evaluating the safety and efficacy of Seraph 100 Microbind Affinity Blood Filter (Seraph 100) use for COVID-19 patients with respiratory failure admitted to the intensive care unit (ICU). The Seraph 100 is a hemoperfusion device containing heparin-coated beads that can bind to, and reduce levels of, some circulating pathogens and inflammatory molecules. This study evaluated whether treatment with the Seraph 100 affected circulating and mucosal antibody levels in critically ill COVID-19 subjects.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!